340 related articles for article (PubMed ID: 37330926)
1. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
Blauvelt A; Chiricozzi A; Ehst BD; Lebwohl MG
Adv Ther; 2023 Aug; 40(8):3410-3433. PubMed ID: 37330926
[TBL] [Abstract][Full Text] [Related]
2. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
Crowley JJ; Warren RB; Cather JC
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL 23 biologics for the treatment of plaque psoriasis.
Vu A; Ulschmid C; Gordon KB
Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
Gottlieb AB; Saure D; Wilhelm S; Dossenbach M; Schuster C; Smith SD; Ramot Y; Thaçi D
J Dermatolog Treat; 2022 Feb; 33(1):54-61. PubMed ID: 32299269
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.
Xu S; Gao X; Deng J; Yang J; Pan F
J Dtsch Dermatol Ges; 2021 Jan; 19(1):47-56. PubMed ID: 33377312
[TBL] [Abstract][Full Text] [Related]
7. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B; Coates LC; Lebwohl MG; Deodhar A; Leibowitz E; Rowland K; Kollmeier AP; Miller M; Wang Y; Li S; Chakravarty SD; Chan D; Shawi M; Yang YW; Thaҫi D; Rahman P
Drug Saf; 2024 Jan; 47(1):39-57. PubMed ID: 37906417
[TBL] [Abstract][Full Text] [Related]
9. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
Boehncke WH; Brembilla NC; Nissen MJ
Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
[TBL] [Abstract][Full Text] [Related]
10. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
11. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
12. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
[TBL] [Abstract][Full Text] [Related]
13. Tildrakizumab: A Review of Phase II and III Clinical Trials.
Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
[TBL] [Abstract][Full Text] [Related]
14. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
Mastorino L; Dapavo P; Susca S; Cariti C; Siliquini N; Verrone A; Stroppiana E; Ortoncelli M; Quaglino P; Ribero S
J Dtsch Dermatol Ges; 2024 Jan; 22(1):34-42. PubMed ID: 37926830
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?
de Brito M; Yiu ZZN
Am J Clin Dermatol; 2021 Sep; 22(5):587-601. PubMed ID: 34292509
[TBL] [Abstract][Full Text] [Related]
16. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Yang K; Oak ASW; Elewski BE
Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128
[TBL] [Abstract][Full Text] [Related]
17. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis.
Fragoulis GE; Siebert S
Musculoskeletal Care; 2022 Nov; 20 Suppl 1(Suppl 1):S12-S21. PubMed ID: 36069174
[TBL] [Abstract][Full Text] [Related]
18. Risankizumab in moderate-to-severe plaque psoriasis.
Serrano L; Maloney V; Gordon KB
Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
[TBL] [Abstract][Full Text] [Related]
19. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
[TBL] [Abstract][Full Text] [Related]
20. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]